Relmada Therapeutics, Inc. (RLMD) — 8-K Filings

8-K Filings (22)

• Relmada Therapeutics Reports Director/Officer Changes & Financials — Dec 15, 2025 Risk: medium
  Relmada Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of
• Relmada Therapeutics Enters Material Definitive Agreement — Nov 5, 2025 Risk: medium
  Relmada Therapeutics, Inc. announced on November 4, 2025, that it entered into a material definitive agreement. The company, formerly known as Camp Nine, Inc.,
• Relmada Therapeutics Files 8-K Report — Nov 4, 2025 Risk: low
  On November 4, 2025, Relmada Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
• Relmada Therapeutics Updates Principal Executive Offices — Sep 17, 2025 Risk: low
  Relmada Therapeutics, Inc. (RLMD) filed an 8-K on September 17, 2025, reporting its principal executive offices are located at 2222 Ponce de Leon Blvd., Floor 3
• Aurorium to Acquire Relmada Therapeutics for $100M — Sep 16, 2025 Risk: medium
  Relmada Therapeutics, Inc. announced on September 15, 2025, that it has entered into a definitive agreement to be acquired by Aurorium LLC. The transaction is v
• Relmada Therapeutics Relocates Principal Offices — Sep 10, 2025 Risk: low
  On September 10, 2025, Relmada Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2222 Ponce
• Relmada Therapeutics Files 8-K — Sep 2, 2025 Risk: low
  Relmada Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting a Regulation FD Disclosure. The company, formerly known as Camp Nine, Inc., is incorporate
• Relmada Therapeutics Faces Delisting Concerns — Jul 23, 2025 Risk: high
  Relmada Therapeutics, Inc. filed an 8-K on July 23, 2025, to report a notice of delisting or failure to meet continued listing requirements. The company, former
• Relmada Therapeutics Terminates Material Agreement — Jul 10, 2025 Risk: medium
  Relmada Therapeutics, Inc. announced on July 7, 2025, the termination of a material definitive agreement. The company, incorporated in Nevada, filed this 8-K re
• Aptinyx to Acquire Relmada Therapeutics — Jun 18, 2025 Risk: medium
  Relmada Therapeutics, Inc. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by Aptinyx Inc. for approximately $1.65 pe
• Relmada Therapeutics Files 8-K — May 27, 2025 Risk: low
  Relmada Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The comp
• Relmada Therapeutics Files 8-K — Apr 28, 2025 Risk: low
  Relmada Therapeutics, Inc. filed an 8-K on April 28, 2025, reporting on other events and financial statements. The company, formerly known as Camp Nine, Inc., i
• Relmada Therapeutics Files 8-K with Key Agreements and Equity Sales — Mar 26, 2025 Risk: medium
  On March 24, 2025, Relmada Therapeutics, Inc. filed an 8-K report detailing several key events. The filing indicates the entry into a material definitive agreem
• Relmada Therapeutics Files 8-K: Material Agreement and Disclosures — Feb 6, 2025 Risk: medium
  On February 3, 2025, Relmada Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported othe
• Relmada Therapeutics to Transfer Listing to OTCQB — Jan 27, 2025 Risk: high
  Relmada Therapeutics, Inc. received a notice on January 21, 2025, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Marke
• Relmada Therapeutics Files 8-K: Board, Officer, and Compensation Updates — Jan 6, 2025 Risk: low
  On January 1, 2025, Relmada Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and certain officers, along with updates to compe
• Relmada Therapeutics Files 8-K Report — Dec 9, 2024 Risk: low
  On December 9, 2024, Relmada Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a corporate event and includes financial s
• Relmada Therapeutics Files 8-K — Dec 4, 2024 Risk: low
  Relmada Therapeutics, Inc. filed an 8-K on December 4, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Relmada Therapeutics Files 8-K on Shareholder Votes and Financials — May 30, 2024 Risk: low
  Relmada Therapeutics, Inc. filed an 8-K on May 30, 2024, reporting on matters submitted to a vote of security holders and financial statements as of May 24, 202
• RELMADA 8-K Signals Executive Changes, Compensation Updates — Jan 11, 2024
  RELMADA THERAPEUTICS, INC. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024, related to the departure or election of direct
• RELMADA THERAPEUTICS Confirms NASDAQ Listing on Jan 4, 2024 — Jan 4, 2024
  RELMADA THERAPEUTICS, INC. filed an 8-K on January 4, 2024, to disclose that its common stock, with a $0.001 par value per share, is registered on The NASDAQ Gl
• RELMADA THERAPEUTICS Reports Officer/Director Changes — Jan 3, 2024
  RELMADA THERAPEUTICS, INC. filed an 8-K on January 3, 2024, to report a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX